ChiCTR-IPC-15007109
结束
/
/
/
2015-09-18
/
/
功能性消化不良
電針灸聯合標準療法治療難治性功能性消化不良:實況隨機對照試驗及經濟學評價
電針灸聯合胃舒錠對比輪候電針灸聯合胃舒錠治療功能性消化不良:實況隨機對照試驗及經濟學評價
電針灸聯合胃舒錠與輪候電針灸聯合胃舒錠治療功能性消化不良患者的效果和成本效益比較
随机平行对照
治疗新技术
Blocked randomization will be used to allocate patients to the two groups, with random block sizes.
Not Applicable
Health andMedical Research Fund
/
132
/
1990-01-01
1990-01-01
/
1. Patients who have completed oesophagogastroduodenoscopy (OGD) with H. pylori negative results, or patients who has tested positive for H. pylori but have completed medication course the for the eradication of H. pylori; 2. Patients with symptoms that fulfill the reference standard for Functional Dyspepsia Postprandial Distress Syndrome, including the presence of either or both of the following symptoms once per week in the past 1 month:postprandial fullness, early satiety. In accordance to the pragmatic approach of this trial, this reference standard is chosen as it reflects presentations of FD patients in real-world clinical settings, increasing the external validity of future results; 3. Voluntary discontinuation of any conventional pharmacological treatments for their functional dyspepsia 2 weeks prior to enrolment, due to perceived ineffectiveness; 4. Hong Kong permanent resident; 5. 18 – 70 years of age.;
请登录查看Patients who fulfill any of the following criteria would be excluded. Criteria will be assessed through patient history, medical record review, or physical examination. 1. Documented diagnosis of esophageal or gastric disease, including esophagitis, gastroesophageal reflux disease (GERD), peptic ulcer, predominant heartburn or acid regurgitation in the past 1 month; 2. Current regular user of non-steroidal anti-inflammatory drugs, anti-depressants or anxiolytic drugs, as defined as daily use in the past 2 months; 3. Patients who had received major abdominal surgery; 4. Patients who are pregnant; 5. Patients who are wearing cardiac pacemaker; 6. Patients who are having underlying major physical illness such as malignancy and infections; 7. Patients are using any dose of PPIs or prokinetics two weeks prior to enrollment; 8. For patients with coexisting IBS as diagnosed by the Manning criteria, exclusion is applied if a patient considers abdominal or bowel symptoms, instead of dyspepsia, as their major complaint. Manning criteria for Irritable Bowel Syndrome (IBS) is positive in this trial when ≥ 4 of the following symptoms are present in the past month: Visible abdominal distension, Pain relieved by a bowel action, More frequent stools with the onset of pain, Looser stools with the onset of pain, Rectal passage of mucus, A sensation of incomplete evacuation.;
请登录查看香港中文大學賽馬會公共衛生與基層醫療學院
/
香港中文大學賽馬會公共衛生與基層醫療學院的其他临床试验
香港中文大學賽馬會公共衛生與基層醫療學院的其他临床试验
最新临床资讯
-
飞眸医疗首例人体临床试验(FIH)成功开展,国产飞秒屈光设备竞逐540亿屈光市场
动脉网-最新2026-09-10
-
和铂医药:超长效靶向TSLP抗体哮喘二期临床取得阳性结果,三期临床已启动
医药笔记2026-09-09
-
医药笔记2026-09-09
-
医药笔记2026-09-09
-
医药笔记2026-09-09
-
医药笔记2026-09-09
-
动脉网-最新2026-09-09
-
药明康德2026-09-09
-
一度医药2026-09-08
-
阿斯利康中国2026-09-08
全球药物研发中心
全球研发数据与行业前沿情报
-
2026-09-26
-
2026-09-26
-
2026-09-26
-
摩熵咨询 20 8
-
摩熵咨询 20 11
-
摩熵咨询 34 56
-
颁布机构:国家药品监督管理局 2026-09-10
-
颁布机构:四川省经济和信息化厅、中共四川省委军民融合发展委员会办公室、四川省教育厅、四川省科学技术厅、四川省人力资源和社会保障厅、四川省卫生健康委员会、四川省医疗保障局、四川省中医药管理局、四川省药品监督管理局 2026-08-04
-
颁布机构:国家医保局 2026-07-31
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
-
2026-09-28
-
2026-09-26
-
2026-09-26
-
摩熵咨询 35 71
-
摩熵咨询 28 60
-
摩熵咨询 34 42
-
颁布机构:国家市场监督管理总局 2026-09-18
-
颁布机构:国家市场监督管理总局 2026-09-17
-
颁布机构:国家市场监督管理总局 2026-08-10
